Although soluble thrombomodulin (sTM) can be elevated in various other processes involving endothelial injury, research suggests that one important disease mechanism in COVID-19 is transition to a procoagulant state of endothelial cells characterized by elevated levels of circulating soluble thrombomodulin (sTM) [21]. This evidence concerns the gene THBD and COVID-19.